MedTech Atlas
Back to medical device regulatory guideAll countries
Asia PacificENPublic regulatory overview

South Korea

Market Overview Population: Approximately 52 million (2024); aging population accelerating Healthcare System: Universal health insurance (National Health Insurance Service, NHIS);...

Updated: 2026-05-04

You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.

Sign in / register for full country report
Reference approval strategy

FDA / CE / MDSAP / NMPA benefits for this market

These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.

US FDA

510(k) / De Novo / PMAModerate benefit

FDA evidence is useful technical and clinical support, but the local authority still performs an independent review.

Likely benefit
  • Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
  • May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
  • Does not remove local holder, language, labeling, fee, import, or post-market obligations.
View topic

EU CE

MDR / IVDRModerate benefit

CE evidence provides a strong technical-file template but does not replace the local review.

Likely benefit
  • Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
  • Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
  • Does not replace local registration or local representative responsibilities outside the CE-recognized route.
View topic

MDSAP

Single QMS auditModerate benefit

MDSAP can help with QMS credibility, especially when issued by a recognized auditing organization.

Likely benefit
  • Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
  • Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
  • Does not authorize product sale and does not replace safety, performance, or clinical evidence.
View topic

China NMPA

China registration / filingDossier reuse only

The NMPA certificate itself has limited effect, but ISO/IEC-aligned test reports, clinical evidence, risk files, and PMS data can be reused after gap assessment.

Likely benefit
  • Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
  • Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
  • Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
View topic

AI Citation Summary

  • Country: South Korea
  • Product line: Medical devices
  • Regulator / source: Regulatory Maturity: High. MFDS (Ministry of Food and Drug Safety, 식품의약품안전처) has a well-established regulatory system; has recently strengthened guidance on digital health devices (SaMD) and AI-based medical devices, aligning with IMDRF; review efficiency is relatively high and timelines are reasonably predictable.
  • Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
  • Typical timeline: Regulatory Maturity: High. MFDS (Ministry of Food and Drug Safety, 식품의약품안전처) has a well-established regulatory system; has recently strengthened guidance on digital health devices (SaMD) and AI-based medical devices, aligning with IMDRF; review efficiency is relatively high and timelines are reasonably predictable.
  • Key fees: Market Characteristics: Market size approximately KRW 10 trillion (approx. USD 7.5 billion) in 2023 — Asia's fourth-largest medical device market. Imports account for approximately 50%. The government actively promotes medical device exports but maintains strict regulation of imports. Innovative medical devices (AI, digital health) are growing rapidly.
  • Local requirement: South Korea medical-device entry should be separated into MFDS classification / notification / certification / approval, local importer / license holder, KGMP / ISO 13485 / MDSAP, Korean labelling, UDI / PMS, HIRA reimbursement, university-hospital procurement, private-specialist channels, and importer-distributor control. Foreign manufacturers usually cannot bypass the Korean importer to hold the import item license directly; registration, importation, quality/safety management, post-market reporting, and channel execution are often tied to the local importer.
  • Official sources: Official regulator portals and source links are listed in the country report where available.
  • Last verified: 2026-05-04
  • Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
  • Preferred citation: MedTech Atlas

Market Overview

  • Population: Approximately 52 million (2024); aging population accelerating
  • Healthcare System: Universal health insurance (National Health Insurance Service, NHIS); dual public and private hospital system; high level of medical technology; a well-developed medical tourism industry. Domestic medical device manufacturers (Samsung Medison, Osstem, etc.) are strong competitors.
  • Market Characteristics: Market size approximately KRW 10 trillion (approx. USD 7.5 billion) in 2023 — Asia's fourth-largest medical device market. Imports account for approximately 50%. The government actively promotes medical device exports but maintains strict regulation of imports. Innovative medical devices (AI, digital health) are growing rapidly.
  • Regulatory Maturity: High. MFDS (Ministry of Food and Drug Safety, 식품의약품안전처) has a well-established regulatory system; has recently strengthened guidance on digital health devices (SaMD) and AI-based medical devices, aligning with IMDRF; review efficiency is relatively high and timelines are reasonably predictable.

Market-Entry Logic

South Korea medical-device entry should be separated into MFDS classification / notification / certification / approval, local importer / license holder, KGMP / ISO 13485 / MDSAP, Korean labelling, UDI / PMS, HIRA reimbursement, university-hospital procurement, private-specialist channels, and importer-distributor control. Foreign manufacturers usually cannot bypass the Korean importer to hold the import item license directly; registration, importation, quality/safety management, post-market reporting, and channel execution are often tied to the local importer.

Entry layer Key question Practical view
Classification and pathway Class 1/2/3/4, notification, certification, or approval? Class 1 is faster; some Class 2 products use certification; Class 3/4 usually need MFDS direct review and fuller clinical / technical evidence
Local license holder Who holds importer business license and import item license? The Korean importer is the license holder; contracts must address certificate control, competing products, and transition after termination
Quality and dossier Are KGMP, ISO 13485, MDSAP, Korean technical documents, and labels complete? MFDS can use overseas quality evidence, but KGMP, Korean dossier, and RFI response quality drive speed
Payment and procurement Is HIRA reimbursement / listing needed, and can university hospitals procure it? Approval does not equal reimbursement; innovative and high-value devices need HIRA and hospital KOL strategy in parallel
Segment dynamics AI/SaMD, IVD, dental, ultrasound, implants, or consumer device? Domestic players are strong in dental, ultrasound, IVD, AI imaging, and digital health; channels differ by segment

Main Players and Channel Map

Type Representative players Market meaning
Regulator / review MFDS, NIFDS, UDIPORTAL, KUDI Determine classification, approval, GMP, UDI, PMS, and innovative-device pathways
Payment / procurement HIRA, NHIS, university hospital purchasing committees, public/private hospital groups Determine reimbursement, price, hospital purchasing, and innovative technology access
Domestic medtech Samsung Medison, Osstem Implant, Vatech, Lunit, Vieworks, Seegene, SD Biosensor Strong in ultrasound, dental, AI imaging, IVD, and diagnostics channels
Multinational device companies Medtronic, J&J MedTech, Abbott, BD, GE HealthCare, Siemens Healthineers, Philips and similar players Retain technical strength in advanced intervention, imaging, diagnostics, and implants
Importers / distributors Korean distributors with importer licenses, specialist service providers, KMDIA network Execute registration, import, quality manager role, service, tenders, and receivables
End settings University hospitals, national tertiary hospitals, private specialists, dental clinics, check-up / laboratory centers Determine high-end equipment, dental, IVD, AI/SaMD, and consumer-device volume
  1. AI/SaMD and digital medical devices are policy priorities: Korea has early guidance and fast-track structures for AI devices, digital therapeutics, and innovative medical devices.
  2. Domestic device competition is rising quickly: Dental, ultrasound, IVD, AI imaging, and diagnostic players shape imported-brand positioning.
  3. Importer-held licenses create channel lock-in risk: When the importer holds the certificate, transfer and market continuity after termination must be agreed upfront.
  4. HIRA reimbursement is the commercial gate: High-value and innovative devices may launch slowly even after MFDS approval if reimbursement negotiation lags.
  5. KGMP, UDI, and PMS execution is strengthening: Quality system, Korean labels, UDI data, and adverse-event reporting require local execution capability.

Regulatory Authority

  • Competent Authority: MFDS (Ministry of Food and Drug Safety, 식품의약품안전처)
  • Official Portals: https://www.mfds.go.kr; Medical Device Registration System: UDIPORTAL / 수입품목허가시스템 (Import Item License System)
  • Key Regulations:
    • Medical Devices Act (의료기기법, enacted 2003, multiple revisions)
    • Enforcement Decree and Enforcement Rules of the Medical Devices Act
    • Regulations on Licensing, Approval, and Review of Medical Devices (MFDS Notice)
    • Medical Device GMP Standard (품질관리기준)
    • Guidance Principles for AI-Based Medical Device Software (2021)

Device Classification System

Local Classification Risk Level EU/FDA Equivalent Description
Class 1 Lowest risk EU Class I / FDA Class I Notification (신고, declaration/filing) system; simple procedure
Class 2 Low-moderate risk EU Class IIa / FDA Class II License (허가) system or Certification (인증) system
Class 3 Moderate-high risk EU Class IIb-III / FDA Class II-III License (허가) system; MFDS direct review
Class 4 Highest risk EU Class III / FDA PMA License (허가) system; most stringent review

Note: Product classification is determined by the MFDS Medical Device Classification Catalogue. Certain Class 2 products may follow an "인증 (Certification)" pathway (analogous to European NB certification), which is comparatively faster; others must follow the MFDS direct license pathway.

Registration Pathways

During the limited-time free period, sign in or register to view the complete medical device country report.